As we transition away from prohibition, we see an increase in opportunity for cannabis research and development. In addition to molecular discovery and medical advancement, we will face challenges. Specifically, we'll need to create and navigate varying paths for botanical cannabis vs pharmaceutical cannabis products.
Our panelists will discuss the current status of cannabis, work being done by pharmaceutical companies to create cannabis medicine, and how this well established industry can harmoniously integrate into the legal market for cannabis. Panelists:
Elias Jackson, Ph.D., Vyripharm Biopharmaceuticals
Mark Bolton, GW Pharmaceuticals
Christian Sederberg, Vicente Sederberg LLP